Session 1 – A Fascinating Year of Biotech Innovation and Investment
Date: 24 July (Wednesday) 14:00 - 16:30 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Chief Science Officer
Dr. Blanchard is responsible for drug discovery, translational medicine , medical science, medical writing , clinical pharmacology , scientific disclosure, statistics and registration application at Innovent. He received a BS in chemistry, a Ph.D. in biochemistry, and a MD from Indiana University. He completed a residency in Internal Medicine and fellowships in Hematology and Medical Oncology at the Brigham and Women’s Hospital, the Dana Farber Cancer Center, and Harvard Medical School. Previously, Dr. Blanchard acted as Senior Vice President in China MDU and External Innovation of Lilly China and has more than 18 years of leading drug discovery and drug development experience.